Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
| Revenue (Most Recent Fiscal Year) | $5.18M |
| Net Income (Most Recent Fiscal Year) | $-7.79M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.77 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.91 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -71.32% |
| Net Margin (Trailing 12 Months) | -71.32% |
| Return on Equity (Trailing 12 Months) | -308.49% |
| Return on Assets (Trailing 12 Months) | -53.66% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.44 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.39 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.56 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-9.26 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-10.99 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 1.49M |
| Free Float | 1.40M |
| Market Capitalization | $6.64M |
| Average Volume (Last 20 Days) | 0.03M |
| Beta (Past 60 Months) | 0.15 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |